Literature DB >> 9512200

Psychological responses to the needle-free Medi-Jector or the multidose Disetronic injection pen in human growth hormone therapy.

G H Verrips1, R A Hirasing, M Fekkes, T Vogels, S P Verloove-Vanhorick, H A Delemarre-Van de Waal.   

Abstract

The aim of the study was to test the hypothesis that daily administration of growth hormone using the Medi-Jector results in fewer adverse psychological responses than needle injection with a multidose injection pen. The Medi-Jector is a needle-free injection device that can deliver growth hormone subcutaneously through jet injection. The group studied consisted of 18 children aged 10 y or over who were participating in a study of the bioequivalence and bioequipotence of the administration of growth hormone through jet injection or needle injection. Previously, all subjects had received growth hormone therapy with commercially available multidose injection pens. The study was designed as a prospective, randomized, two-period cross-over trial. A questionnaire was used to assess psychological responses such as non-compliance, opinion on ease of preparation, affective responses to administration and local side-effects, as well as overall preference. In addition, the subjects kept a diary during the study. The subjects found the Medi-Jector less offputting (p < 0.01), less painful with respect to both frequency (p < 0.04) and intensity (p < 0.01) and less unpleasant (p < 0.05) than a multidose injection pen with a 28G needle (p < 0.01). No difference in compliance was detected. Most subjects preferred the Medi-Jector for future use (p < 0.05). The mean score on a 1-10 point scale (10 is excellent) was 7.9 (SD 1.4) for the Medi-Jector and 6.8 (SD 2.3) for the multidose injection pen (p < 0.08). The prevalence of visible bruises each day was higher (p < 0.01) with the Medi-Jector (2.5, SD 2.1) than with the multidose injection pen (0.7, SD 1.1), but children showed indifferent affective responses to bruising. Thirteen out of 18 subjects decided to continue therapy with the Medi-Jector (p < 0.06). It is concluded that use of the Medi-Jector in growth hormone therapy tends to lead to fewer adverse psychological responses than a multidose injection pen with 28G needles.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9512200     DOI: 10.1080/08035259850157589

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  7 in total

1.  Abnormalities of GH secretion in a young girl with Floating-Harbor syndrome.

Authors:  S Cannavò; L Bartolone; D Lapa; M Venturino; B Almoto; A Violi; F Trimarchi
Journal:  J Endocrinol Invest       Date:  2002-01       Impact factor: 4.256

2.  Efficacy of needle-free administration of recombinant human growth hormone in adults with growth hormone deficiency.

Authors:  Alberto M Pereira; Agatha A van der Klaauw; Hans P F Koppeschaar; Jan W A Smit; Sjoerd W van Thiel; Jaap van Doorn; Nienke R Biermasz; Ferdinand Roelfsema; Johannes A Romijn
Journal:  Br J Clin Pharmacol       Date:  2006-04       Impact factor: 4.335

3.  Understanding and meeting the needs of those using growth hormone injection devices.

Authors:  Hervé Dumas; Paris Panayiotopoulos; Dorothy Parker; Vincent Pongpairochana
Journal:  BMC Endocr Disord       Date:  2006-10-11       Impact factor: 2.763

4.  Maintaining persistence and adherence with subcutaneous growth-hormone therapy in children: comparing jet-delivery and needle-based devices.

Authors:  Helen A Spoudeas; Priti Bajaj; Nathan Sommerford
Journal:  Patient Prefer Adherence       Date:  2014-09-17       Impact factor: 2.711

5.  Adherence in children with growth hormone deficiency treated with r-hGH and the easypod™ device.

Authors:  S Loche; M Salerno; P Garofalo; G M Cardinale; M R Licenziati; G Citro; M Caruso Nicoletti; M Cappa; S Longobardi; M Maghnie; R Perrone
Journal:  J Endocrinol Invest       Date:  2016-07-12       Impact factor: 4.256

6.  Pharmacokinetics of recombinant human growth hormone administered by cool.click 2, a new needle-free device, compared with subcutaneous administration using a conventional syringe and needle.

Authors:  Chris Brearley; Anthony Priestley; James Leighton-Scott; Michel Christen
Journal:  BMC Clin Pharmacol       Date:  2007-10-08

7.  Transjecting growth hormone: continuous nightmare or controlled nuisance? Evaluation of a new needle-free device.

Authors:  Ad A Kaptein
Journal:  Patient Prefer Adherence       Date:  2013-07-24       Impact factor: 2.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.